The Filing Desk

Nektar Therapeutics vs Nuvation Bio

Nektar Therapeutics NKTR · Nuvation Bio NUVB · Pharmaceuticals

Nuvation Bio reported revenue of $63 million in fiscal 2025, about the same as Nektar Therapeutics' $55 million in fiscal 2025. Nektar Therapeutics' revenue fell 43.9% in its latest year, and Nuvation Bio's grew 699.0%. Nektar Therapeutics had an operating margin of -253.7%, against -338.7% at Nuvation Bio. Free cash flow was −$209 million at Nektar Therapeutics and −$181 million at Nuvation Bio.

Side by side

Nektar TherapeuticsNuvation Bio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$55M$63M
Revenue growth−43.9%699.0%
Revenue growth a year, last 5 years−18.4%—
Gross margin100.0%—
Operating margin−253.7%−338.7%
Net margin−297.1%−325.3%
Free cash flow−$209M−$181M
Free cash flow margin−377.8%−288.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count23.1%27.1%
Last close$37.27$3.99
P/E at the last close——
Insider trades, last 12 monthssold $2.4 million—
Piotroski F-score2 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Nektar TherapeuticsNuvation Bio
Operating margin
Percent of revenue
Nektar TherapeuticsNuvation Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Nektar TherapeuticsNuvation Bio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nektar Therapeutics and Nuvation Bio pages.